Top 5 Takeaways Decline in HIV Testing and Diagnoses: From 2019 to 2020, there was a 17% decrease in new HIV diagnoses reported to the CDC, accompanying a significant decline
Category: MMWR Booster
Top 5 Takeaways Low Incidence of Severe Illness Post-Paxlovid: Hospitalizations or ED encounters for COVID-19 within 5-15 days after Paxlovid treatment were rare, occurring in <1% of patients, suggesting Paxlovid’s
Top 5 Takeaways Lagevrio and Paxlovid showed effectiveness in preventing hospitalization and death. These oral antiviral drugs have been crucial for patients with mild to moderate COVID-19 who are at
Top 5 Takeaways Significant number of pediatric hepatitis cases: From October 1, 2021, to June 15, 2022, 296 pediatric patients in the U.S. were diagnosed with hepatitis of unknown etiology,
Top 5 Takeaways FDA Approvals and ACIP Recommendations: The FDA issued Emergency Use Authorizations for the Moderna and Pfizer-BioNTech COVID-19 vaccines for children aged 6 months–5 years and 6 months–4
Top 5 Takeaways Anemia prevalence increased among pregnant WIC participants. From 2008 to 2018, there was a 13% increase in anemia prevalence among pregnant women enrolled in WIC, from 10.1%
Top 5 Takeaways Increased Protection for Immunocompromised Adults: The updated 2023–2024 (monovalent XBB.1.5) COVID-19 vaccine offers increased protection against COVID-19-associated hospitalizations for adults aged ≥18 years with immunocompromising conditions. Low
Top 5 Takeaways Increased TB Case Counts Across All Groups: In 2023, the U.S. saw an increase in tuberculosis (TB) cases across all age groups, U.S.-born and non-U.S.–born persons, and
Top 5 Takeaways Increased Detection of Measles Vaccine Virus: Approximately 1% of syndromic PCR panels conducted by a commercial laboratory tested positive for measles, mainly in children recently vaccinated against
Top 5 Takeaways Growing resistance: The prevalence of antibiotic-resistant strains of Neisseria gonorrhoeae, particularly to ceftriaxone, has significantly increased in China from 2017 to 2022, with resistance to ceftriaxone approximately